As of November 6, 2026, BlossomHill Therapeutics, Inc. is a publicly traded company (Nasdaq: BLSM). The largest holder reporting an active stake on Schedule 13D is Cormorant Asset Management, LP, at 11.8%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Perceptive Advisors (5.9%), Vivo Innovation Fund II Holdings, L.P. (5.5%) (Schedule 13D, August 13, 2026).
Is this your company?
About to sign with, pay or invest in BlossomHill Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is BlossomHill Therapeutics, Inc. a real, registered company?
- BlossomHill Therapeutics, Inc. files with the SEC under CIK 1839970 (its SEC filings).
- Its shares are listed under the ticker BLSM on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under BlossomHill Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names OrbiMed (filed 2026-08-18).
Who are BlossomHill Therapeutics, Inc.'s owners and officers?
BlossomHill Therapeutics, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13D, 2026-08-18).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-12-10)
- : Executive Officer, Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D, 2026-08-18 | Orbimed Advisors LLC | 8.9% |
| Schedule 13G, 2026-08-17 | Vivo Innovation Fund Ii Holdings, L.P. | 5.5% |
| Schedule 13G, 2026-08-14 | Perceptive Advisors LLC | 5.9% |
| Schedule 13D, 2026-08-13 | Cormorant Asset Management, LP | 11.8% |
Questions about who owns BlossomHill Therapeutics, Inc.
Who owns BlossomHill Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of BlossomHill Therapeutics, Inc.: Cormorant Asset Management, LP (11.8%, Schedule 13D, filed 2026-08-13), Orbimed Advisors LLC (8.9%, Schedule 13D, filed 2026-08-18), Perceptive Advisors LLC (5.9%, Schedule 13G, filed 2026-08-14) and Vivo Innovation Fund Ii Holdings, L.P. (5.5%, Schedule 13G, filed 2026-08-17).
Who are the largest shareholders of BlossomHill Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of BlossomHill Therapeutics, Inc. on this page are Cormorant Asset Management, LP (11.8%), Orbimed Advisors LLC (8.9%) and Perceptive Advisors LLC (5.9%).
When did Cormorant Asset Management, LP buy into BlossomHill Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Cormorant Asset Management, LP on this page is the Schedule 13D, filed 2026-08-13, reporting 11.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on BlossomHill Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BlossomHill Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BlossomHill Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own BlossomHill Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chairman and a director: 3,973,138 shares (12.5% of shares outstanding), 1,067,121 held directly and 2,906,017 indirectly (Form 4, 2026-08-10).
- , the chief executive and president: 3,973,138 shares (12.5% of shares outstanding), 1,067,121 held directly and 2,906,017 indirectly (Form 4, 2026-08-10).
- Cormorant Global Healthcare Master Fund, LP, a 10% owner: 3,614,034 shares (11.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-08-10).
- , a director and 10% owner: 3,614,034 shares (11.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-08-10).
- Cormorant Private Healthcare Fund VI, LP, a 10% owner: 3,614,034 shares (11.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-08-10).
Shares outstanding: 31,784,909 as of 2026-09-16, from the company's latest SEC cover page.
How much has BlossomHill Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-12-10 | $84.15M | $84.15M |
| Form D, 2024-01-02 | $88.65M | $100M |
Latest IPO step: BlossomHill Therapeutics, Inc. filed its final IPO prospectus, ticker BLSM (424B4, 2026-08-07).
IPO filings: 424B4, 2026-08-07, S-1/A, 2026-08-03, S-1, 2026-07-17; ticker BLSM on Nasdaq Global Select Market.
Keep reading
More on BlossomHill Therapeutics, Inc. and the records around it.
The people at BlossomHill Therapeutics, Inc.
- CARL GORDON is also named on 1 other Form D filing: Avenzo Therapeutics, Inc. (Sep 2025)
BlossomHill Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- IPO filing Aug 2026
- Form D filing Dec 2025
Companies that share a holder
- Cormorant Global Healthcare Master Fund, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/blossomhill-therapeutics